Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy

ClinicalTrials.gov ID: NCT03332771

Public ClinicalTrials.gov record NCT03332771. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Placebo Added to Metformin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin Monotherapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary Objective: To demonstrate the non-inferiority of Sotagliflozin 400 milligrams (mg) compared to Glimepiride on hemoglobin A1c (HbA1c) reduction at Week 52 in participants with Type 2 Diabetes (T2D) who have inadequate glycemic control with metformin. Secondary Objectives: To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in body weight, systolic blood pressure (SBP) in participants with baseline SBP ≥130 millimeter of mercury (mmHg), SBP in all participants, and proportion of participants with at least 1 documented symptomatic hypoglycemic event (≤70 milligrams per deciliter \[mg/dL\]). * To demonstrate the superiority of Sotagliflozin 400 mg compared to placebo on change in HbA1c, body weight, SBP in participants with baseline SBP ≥130 mmHg, SBP in all participants. * To demonstrate the superiority of Sotagliflozin 200 mg compared to placebo on change in HbA1c. * To demonstrate the non-inferiority of Sotagliflozin 400 mg compared to Glimepiride on change in HbA1c. * To demonstrate the superiority of Sotagliflozin 400 mg compared to Glimepiride on change in HbA1c. * To evaluate the safety and tolerability of Sotagliflozin compared to Glimepiride and placebo.

Study identification

NCT ID
NCT03332771
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Lexicon Pharmaceuticals
Industry
Enrollment
954 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2017
Primary completion
Aug 5, 2019
Completion
Sep 5, 2019
Last update posted
May 10, 2021

2017 – 2019

United States locations

U.S. sites
115
U.S. states
29
U.S. cities
104
Facility City State ZIP Site status
Investigational Site Number 8407040 Birmingham Alabama 35205
Investigational Site Number 8407048 Birmingham Alabama 35233-2110
Investigational Site Number 8407035 Little Rock Arkansas 72211
Investigational Site Number 8407051 Anaheim California 92801-2417
Investigational Site Number 8407065 Canoga Park California 91301
Investigational Site Number 8407078 Carmichael California 95608
Investigational Site Number 8407089 Downey California 90242
Investigational Site Number 8407011 Gold River California 95670
Investigational Site Number 8407044 Greenbrae California 94904
Investigational Site Number 8407006 Huntington Park California 90255-2911
Investigational Site Number 8407037 Lemon Grove California 91945
Investigational Site Number 8407100 Lomita California 90717
Investigational Site Number 8407033 Long Beach California 90806
Investigational Site Number 8407019 Los Angeles California 90057-3507
Investigational Site Number 8407098 Northridge California 91325-5409
Investigational Site Number 8407094 Norwalk California 90650
Investigational Site Number 8407106 Pomona California 91766
Investigational Site Number 8407096 Rancho Cucamonga California 91730
Investigational Site Number 8407036 Sacramento California 95821
Investigational Site Number 8407084 Tarzana California 91356-3551
Investigational Site Number 8407034 Upland California 91786-4070
Investigational Site Number 8407032 Van Nuys California 91405
Investigational Site Number 8407004 Walnut Creek California 94598
Investigational Site Number 8407117 Wildomar California 92595
Investigational Site Number 8407045 Colorado Springs Colorado 80920-8075
Investigational Site Number 8407074 Bradenton Florida 34201
Investigational Site Number 8407027 Clearwater Florida 33761
Investigational Site Number 8407103 Cooper City Florida 33024
Investigational Site Number 8407021 Coral Gables Florida 33134
Investigational Site Number 8407062 Lake Worth Florida 33467
Investigational Site Number 8407121 Ocoee Florida 34761
Investigational Site Number 8407024 Orlando Florida 32825-4454
Investigational Site Number 8407038 Palmetto Bay Florida 33157-5503
Investigational Site Number 8407093 Pembroke Pines Florida 33026-3924
Investigational Site Number 8407107 Spring Hill Florida 34609
Investigational Site Number 8407091 Tampa Florida 33619
Investigational Site Number 8407113 Tampa Florida 33634
Investigational Site Number 8407092 West Palm Beach Florida 33401
Investigational Site Number 8407115 Winter Haven Florida 33880
Investigational Site Number 8407017 Chicago Illinois 60607
Investigational Site Number 8407018 Elgin Illinois 60124
Investigational Site Number 8407046 Gurnee Illinois 60031
Investigational Site Number 8407119 Springfield Illinois 62711
Investigational Site Number 8407075 Waterloo Iowa 50702
Investigational Site Number 8407120 West Des Moines Iowa 50265
Investigational Site Number 8407095 Topeka Kansas 66606-2806
Investigational Site Number 8407083 Wichita Kansas 67205-1138
Investigational Site Number 8407043 Lexington Kentucky 40503-2517
Investigational Site Number 8407087 Lexington Kentucky 40503
Investigational Site Number 8407060 Lake Charles Louisiana 70601
Investigational Site Number 8407058 New Orleans Louisiana 70119
Investigational Site Number 8407009 New Orleans Louisiana 70124
Investigational Site Number 8407079 Zachary Louisiana 70791-4010
Investigational Site Number 8407085 Baltimore Maryland 21237
Investigational Site Number 8407001 Rockville Maryland 20852
Investigational Site Number 8407069 Troy Michigan 48098-6334
Investigational Site Number 8407110 Olive Branch Mississippi 38654
Investigational Site Number 8407054 Bridgeton Missouri 63044
Investigational Site Number 8407049 Norfolk Nebraska 68701
Investigational Site Number 8407039 Omaha Nebraska 68114
Investigational Site Number 8407061 Papillion Nebraska 68046-3136
Investigational Site Number 8407108 Las Vegas Nevada 89106-4132
Investigational Site Number 8407050 Albuquerque New Mexico 87106
Investigational Site Number 8407116 New York New York 10016-6402
Investigational Site Number 8407086 New York New York 10029
Investigational Site Number 8407122 New York New York 10036
Investigational Site Number 8407123 West Seneca New York 14224
Investigational Site Number 8407020 Greensboro North Carolina 27408
Investigational Site Number 8407114 Lenoir North Carolina 28645-8981
Investigational Site Number 8407015 Morehead City North Carolina 28557
Investigational Site Number 8407030 Salisbury North Carolina 28144-2742
Investigational Site Number 8407041 Wilmington North Carolina 28401-6638
Investigational Site Number 8407101 Winston-Salem North Carolina 27103
Investigational Site Number 8407099 Cincinnati Ohio 45245
Investigational Site Number 8407081 Lyndhurst Ohio 44124-2467
Investigational Site Number 8407057 Norman Oklahoma 73069
Investigational Site Number 8407073 Oklahoma City Oklahoma 73104-3252
Investigational Site Number 8407068 Eugene Oregon 97404
Investigational Site Number 8407104 Beaver Pennsylvania 15009-1957
Investigational Site Number 8407025 Hatboro Pennsylvania 19040-2045
Investigational Site Number 8407053 Lansdale Pennsylvania 19446-1002
Investigational Site Number 8407016 Charleston South Carolina 29407
Investigational Site Number 8407071 Greer South Carolina 29651-1817
Investigational Site Number 8407022 Mt. Pleasant South Carolina 29464
Investigational Site Number 8407031 Mt. Pleasant South Carolina 29464
Investigational Site Number 8407014 Jefferson City Tennessee 37760
Investigational Site Number 8407002 Knoxville Tennessee 37938
Investigational Site Number 8407056 Memphis Tennessee 38163
Investigational Site Number 8407026 Austin Texas 78735-8982
Investigational Site Number 8407029 Beaumont Texas 77702
Investigational Site Number 8407070 Carrollton Texas 75010
Investigational Site Number 8407102 Corpus Christi Texas 78414-4173
Investigational Site Number 8407023 Dallas Texas 75230
Investigational Site Number 8407111 Dallas Texas 75231
Investigational Site Number 8407013 Fort Worth Texas 76164
Investigational Site Number 8407080 Houston Texas 77040
Investigational Site Number 8407088 Houston Texas 77095-2856
Investigational Site Number 8407090 Katy Texas 77450
Investigational Site Number 8407042 Lampasas Texas 76550-1820
Investigational Site Number 8407067 Lufkin Texas 75904
Investigational Site Number 8407118 Lufkin Texas 75904
Investigational Site Number 8407059 McAllen Texas 78504
Investigational Site Number 8407012 Mesquite Texas 75149
Investigational Site Number 8407007 Plano Texas 75075
Investigational Site Number 8407005 San Antonio Texas 78218
Investigational Site Number 8407064 San Antonio Texas 78229-3818
Investigational Site Number 8407010 Schertz Texas 78154
Investigational Site Number 8407076 Splendora Texas 77372
Investigational Site Number 8407063 Clinton Utah 84015
Investigational Site Number 8407055 Holladay Utah 84117-7054
Investigational Site Number 8407097 Ogden Utah 84405
Investigational Site Number 8407072 Salt Lake City Utah 84102-1553
Investigational Site Number 8407124 Manassas Virginia 20110-4421
Investigational Site Number 8407105 Richmond Virginia 23249-0001
Investigational Site Number 8407028 Renton Washington 98055

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03332771, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 10, 2021 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03332771 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →